Quick Facts

• Primary Use: Management of intermittent claudication
• Associated Condition: Chronic occlusive arterial disease of the limbs
• Potential Benefit: May assist in improving function and managing symptoms

Recital, which contains the substance pentoxifylline, is a prescription treatment designated for the management of symptoms associated with intermittent claudication. This condition is characterized by leg pain or discomfort that occurs during walking and is commonly linked to chronic occlusive arterial disease of the limbs.

The administration of this medication is typically employed to help improve blood flow in the affected extremities. This may contribute to an increase in the distance a person can walk before experiencing discomfort. It is important to note that while this medicine may offer symptomatic relief and potentially improve limb function, it is not intended to take the place of more definitive therapies, such as surgical procedures, for peripheral vascular disease.

The therapeutic role of this compound is generally considered as part of an overall management plan for the condition.

Who Can and Cannot Use Recital (Pentoxifylline)?

The eligibility for using Recital (Pentoxifylline) is defined by regulatory agencies based on pre-existing conditions and population factors, establishing absolute prohibitions and restricted use categories.

Contraindicated Populations

Use of this medicine is prohibited in patients with a history of intolerance to Pentoxifylline or other methylxanthine derivatives (such as caffeine or theophylline). It is also contraindicated for patients who have experienced recent cerebral or retinal hemorrhage, acute myocardial infarction (MI), or those with peptic ulcers or a recent history thereof.

Age and Physiological Restrictions

Condition-Specific Limitations

Use is not recommended in patients with marked impairment of kidney function (Creatinine Clearance < 30 mL/min) or severe impairment of liver function, as drug exposure may be significantly increased. The medicine requires careful monitoring in patients who have a risk of hemorrhage or those with low blood pressure or severe cardiac arrhythmias.

Interactions with other medicines and products

Official regulatory information for Pentoxifylline defines interaction risk through specific prohibitions and documented effects on drug exposure and pharmacodynamics.

The interaction profile primarily involves pharmacokinetic changes, where certain medicines or physiological states increase the systemic levels of pentoxifylline. Additionally, specific warnings exist for pharmacodynamic reinforcement, necessitating caution with drugs that affect coagulation or blood pressure due to documented additive effects. No timing-based separation rules are explicitly mandated for co-administered medicines.

The primary action of pentoxifylline is molecular inhibition, specifically functioning as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, targeting the PDE Type III and Type IV isoforms. This interaction prevents the hydrolysis of the intracellular second messenger cyclic adenosine monophosphate ( cAMP), thereby increasing its concentration. This elevated cAMP level initiates the signal cascade that underlies the resulting hemorheologic and immunomodulatory effects. The cAMP-mediated signaling enhances the deformability (flexibility) of red blood cells (erythrocytes), reducing the resistance to flow in the microvasculature. Concurrently, the mechanism reduces blood viscosity by suppressing the aggregation and adherence of platelets and leukocytes, contributing to optimized flow characteristics. Furthermore, the elevated cAMP suppresses the activity of the transcription factor Nuclear Factor-kappa B ( NF-kappa B), resulting in a decreased synthesis and release of major pro-inflammatory mediators, such as Tumor Necrosis Factor-alpha ( TNF-alpha), which affects inflammatory signaling in the vascular system.

How to Use Recital (Pentoxifylline)

Administration Overview

Pentoxifylline is administered through two routes: primarily oral, via the extended-release tablet, and sometimes via intravenous (IV) injection as a solution. The most common form used for ongoing therapy is the 400 mg extended-release tablet.

Standard Dosing and Timing

The general principle for adult oral administration begins with a standard dose of 400 mg per tablet. The usual starting and maintenance frequency is three times a day (TID), which amounts to a typical maximum total daily intake of 1200 mg. To maintain the extended-release profile and prevent rapid absorption, the tablet must be swallowed whole and must not be crushed or chewed. Furthermore, administration is specifically conditioned to be taken with meals to help minimize potential gastrointestinal discomfort.

Usage Patterns and Adjustments

Treatment must generally be continued for at least eight weeks before a comprehensive assessment of the medicine’s effectiveness is made. A significant procedural adjustment is required for patients with impaired organ function. For individuals with severe renal impairment (creatinine clearance less than or equal to 30 mL/min), the dose must be reduced (e.g., to 400 mg once or twice daily). A similar dose reduction may be implemented if a patient experiences intolerance to the standard three-times-daily regimen, adjusting the frequency to twice daily. While no specific rules exist for older adults based solely on age, cautious dose selection is standard practice. Pediatric use has not been formally established.

Research Evidence / Overview of Studies

Phase I & II: Tolerability and Dosing

Early-stage research focused primarily on identifying a tolerable dose range, as investigators sought to document preliminary information on patient tolerability.

• Tolerability Profile: Data reported on the compound's tolerability profile in adult study participants.
• Pharmacokinetics: Initial studies examined how the compound is absorbed, distributed, metabolized, and excreted. These initial pharmacokinetic studies guided the design of later-stage trials.

Phase III: Evaluation in Pain Management

Later-stage research examined the compound in larger participant groups across various pain conditions.

Post-Operative Pain

Studies evaluated the compound in the context of moderate-to-severe pain, including in post-operative recovery settings.

• Clinical research examined the compound’s influence on patient-reported pain scores within 48 hours of administration, and recorded data on this measure.

Chronic Non-Cancer Pain

Research investigated the long-term potential of the compound in managing chronic pain conditions.

• Trial findings indicated that data on changes in chronic pain were recorded over a 6-month trial period.
• The research evaluated the compound’s side-effect profile in comparison studies.

Drug Interactions

Phase III trials investigated the compound’s use in combination with standard NSAIDs. Data from these clinical studies were reported in relevant publications.

Key Studies & References Pentoxifylline - StatPearls - NCBI Bookshelf (Review of Indications and Pharmacokinetics)

Common questions about Recital (Pentoxifylline) (FAQ)

Q: Is Recital classified as a blood thinner or an antiplatelet medication?

Recital (pentoxifylline) is officially classified as a hemorheologic agent, meaning it works to modify the physical properties of your blood to improve flow. While it is not strictly defined as a primary 'blood thinner' or antiplatelet drug, official documents note that it can have additive effects when taken with these medications. This additive effect may increase the documented risk of bleeding.

Q: How long does it typically take to start noticing the effects of Recital?

According to official patient information, it typically takes time for the medicine's effects to become noticeable. Initial improvement in symptoms may begin after about two to four weeks of consistent treatment. Official guidance indicates that treatment should generally be continued for up to eight weeks before a full assessment of the benefits is completed.

Q: What are the severe side effects of Recital that are listed in regulatory information?

Regulatory documents list several serious adverse reactions, which are rare but documented. The most critical safety concern is the risk of hemorrhage, or serious bleeding, including in the brain or eyes. Other serious potential risks include severe systemic allergic reactions (anaphylaxis) and certain hepatobiliary disorders, such as hepatitis or jaundice.

Q: Are there any known interactions between Recital and common over-the-counter pain relievers?

Official labeling formally prohibits the co-administration of Recital with Ketorolac, which is a type of pain reliever. Caution is noted for its use alongside other drugs that increase the risk of bleeding, including many common nonsteroidal anti-inflammatory drugs (NSAIDs). The need for monitoring may be associated with the use of these medicines together.

Q: Can Recital be taken safely with other medications used to manage blood pressure?

Official documents indicate that pentoxifylline may potentiate—or increase the effects of—medications used to manage high blood pressure. Due to this potential, which could cause a small decrease in blood pressure, this combination necessitates that blood pressure monitoring be considered.

Q: Is there any information available about taking Recital during pregnancy?

Recital is classified by the FDA as Pregnancy Category C. Official documents state that this medicine should be used during pregnancy only if the potential benefit to the patient is determined to justify the potential risk to the fetus.

Q: Is Recital the brand name, and what is the generic component?

Recital is a brand name under which the medicine is sometimes marketed. The active ingredient, which performs the therapeutic action, is Pentoxifylline.

Q: What should a patient know about taking Recital before having surgery?

Regulatory guidance highlights the importance of informing a doctor or dentist about the use of Recital before any surgery or procedure. This is a standard safety precaution due to the medicine's documented potential to increase the risk of bleeding when used alongside anti-clotting agents.

Q: Does taking an antacid affect the absorption of Recital?

Information from official drug labeling indicates that taking antacids does not appear to significantly interfere with the absorption of pentoxifylline into the body. This finding comes from comparative studies conducted during the drug's review process.

Q: How is Recital described as helping with circulation in the legs?

According to official patient information, Recital is prescribed to help reduce symptoms like pain, cramping, and weakness in the legs caused by intermittent claudication. It is described as working by increasing blood flow and supporting the delivery of oxygen to the muscles.

Q: Does the time of day matter when taking Recital?

Regulatory guidance suggests that pentoxifylline is usually taken three times each day, with meals. Official guidance suggests that doses should be spaced evenly throughout your waking hours to maintain consistent drug levels in the bloodstream.

Q: What type of monitoring or lab tests might be required while on Recital?

Official safety information states that if Recital is used in combination with anticoagulants, monitoring of anti-coagulant activity (such as prothrombin time) may be required. Frequent blood tests may also be needed during the course of treatment.

Q: What research has been conducted on Recital for chronic kidney disease (CKD)?

While Recital is not approved for kidney disease, formal research studies have examined the use of pentoxifylline for complications like diabetic kidney disease (DKD). These studies have documented outcomes related to anti-proteinuric effects and observed changes in the rate of estimated glomerular filtration rate loss.

Q: Are there studies that examine the use of Recital for conditions like Peyronie's disease?

Pentoxifylline is only approved for peripheral vascular disease. However, various research studies have investigated its potential application for other conditions, including Peyronie's disease. This research falls outside the official approved uses of the medication.

Q: What research themes are currently being explored regarding Recital's potential uses?

Official registries, such as those maintained by the NIH, show that research is ongoing to explore potential uses for pentoxifylline. Current themes include studies on the drug's effect on diabetic nephropathy, which is a complication of diabetes affecting the kidneys.

Q: How is the medicine described as affecting microcirculation in the extremities?

Regulatory-supported information describes the medicine's action on the body's smallest blood vessels, or microcirculation. It achieves this by decreasing the thickness (viscosity) of the blood and enhancing the flexibility of red blood cells, properties which are associated with improved passage through narrow vessels.

Q: Can this medication cause easy bruising or increase the risk of bleeding?

Yes, the potential for easy bruising or bleeding is a known risk associated with this medicine. Official safety information lists this as a serious side effect. The medicine is formally contraindicated (prohibited) in patients with conditions that already put them at high risk of hemorrhage.

Q: What are the general guidelines for patients who miss a dose of Recital?

Regulatory-based patient guidance states that a missed dose may be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the guidance is to skip the missed dose and resume the regular schedule, rather than taking two doses.

Q: Why do official documents advise caution for people who have had a recent major operation?

Official documents advise caution for people who have had a recent major surgery. This is due to the drug’s documented effect on blood flow properties, which can potentially increase the risk of bleeding during the post-operative recovery period.

Q: What is the official information regarding the use of Recital for diabetic neuropathy pain?

Pentoxifylline is not approved for the treatment of pain. However, research studies have investigated its effects on symptoms associated with diabetic distal polyneuropathy, which is nerve damage related to diabetes. Some research reports observations related to the reduction of certain symptoms.

Q: Can patients who have stomach ulcers take Recital?

No. According to the official regulatory document on eligibility, the medicine is contraindicated—meaning its use is prohibited—in patients who currently have, or have a recent history of, a stomach or intestinal ulcer.

Q: Are there any reported interactions between Recital and tobacco products?

Patient warnings based on regulatory information note that smoking tobacco may potentially worsen the underlying circulation condition by causing further narrowing of the blood vessels. Official warnings suggest that this behavior may interfere with the intended beneficial effects of the medicine.

Q: Can Recital be used for circulation problems that are not intermittent claudication?

The approved indication for Recital (pentoxifylline) by regulatory bodies such as the FDA, MHRA, and TGA is solely for the treatment of symptoms associated with intermittent claudication. This means it is not approved for other types of circulation problems.

Q: Is the medication known to cause problems with sleep or insomnia?

Official documents related to side effects list insomnia (difficulty sleeping) as a potential adverse reaction affecting the Central Nervous System. This is noted in the regulatory warnings about common side effects.

How to Store and Dispose of Recital (Pentoxifylline)?

Storage Requirements

Pentoxifylline tablets must be stored at controlled room temperature, ideally between 20 C to 25 C (68 F to 77 F). Brief excursions are permitted between 15 C to 30 C (59 F to 86 F). It is essential to keep the medication in its original container and ensure the cap is tightly closed to maintain product integrity. The tablets must be protected from excessive heat, moisture, and direct light. For safety, always keep this and all medications securely out of the reach of children.

Disposal Procedures

Do not dispose of this medicine by flushing it down a toilet unless explicitly instructed to do so by a healthcare professional or regulatory body. The preferred method for discarding unused or expired pentoxifylline is through a community drug take-back program. If such a program is not available, the medication should be mixed with an undesirable substance, such as dirt or cat litter, placed in a sealed bag or container, and disposed of in the household trash, following local regulations.